51 related articles for article (PubMed ID: 21550659)
1. Inhibition of PRAME expression causes cell cycle arrest and apoptosis in leukemic cells.
Tanaka N; Wang YH; Shiseki M; Takanashi M; Motoji T
Leuk Res; 2011 Sep; 35(9):1219-25. PubMed ID: 21550659
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the apoptotic response of human leukemia cells to organosulfur compounds.
Wong WW; Boutros PC; Wasylishen AR; Guckert KD; O'Brien EM; Griffiths R; Martirosyan AR; Bros C; Jurisica I; Langler RF; Penn LZ
BMC Cancer; 2010 Jul; 10():351. PubMed ID: 20598143
[TBL] [Abstract][Full Text] [Related]
3. Tumor antigen PRAME is a potential therapeutic target of p53 activation in melanoma cells.
Lee YK; Heo HH; Kim N; Park UH; Youn H; Moon EY; Kim EJ; Um SJ
BMB Rep; 2024 Jun; ():. PubMed ID: 38835116
[TBL] [Abstract][Full Text] [Related]
4. The germline genetics of mild-to-moderate penetrance: An intriguing role of
Hamdan D; Nguyen VT; Paris J; Leboeuf C; El Bouchtaoui M; Espié M; Janin A; Falgarone G; Di Benedetto M; Bousquet G
Genes Dis; 2024 May; 11(3):101003. PubMed ID: 38274368
[No Abstract] [Full Text] [Related]
5. Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?
Al-Khadairi G; Decock J
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31311081
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of PRAME Suppresses Proliferation and Promotes Apoptosis in Hepatocellular Carcinoma Through the Activation of P53 Mediated Pathway.
Zhu H; Wang J; Yin J; Lu B; Yang Q; Wan Y; Jia C
Cell Physiol Biochem; 2018; 45(3):1121-1135. PubMed ID: 29439259
[TBL] [Abstract][Full Text] [Related]
7. Targeting PRAME for acute myeloid leukemia therapy.
Yang J; Chen M; Ye J; Ma H
Front Immunol; 2024; 15():1378277. PubMed ID: 38596687
[TBL] [Abstract][Full Text] [Related]
8. Concomitant inhibition of the thioredoxin system and nonhomologous DNA repair potently sensitizes Philadelphia-positive lymphoid leukemia to tyrosine kinase inhibitors.
Komorowski L; Dabkowska A; Madzio J; Pastorczak A; Szczygiel K; Janowska M; Fidyt K; Bielecki M; Hunia J; Bajor M; Stoklosa T; Winiarska M; Patkowska E; Firczuk M
Hemasphere; 2024 Mar; 8(3):e56. PubMed ID: 38486859
[TBL] [Abstract][Full Text] [Related]
9. Expression of Preferentially Expressed Antigen in Melanoma, a Cancer/Testis Antigen, in Carcinoma In Situ of the Urinary Tract.
Fujii S; Ishida M; Komura K; Nishimura K; Tsujino T; Saito T; Taniguchi Y; Murakawa T; Azuma H; Hirose Y
Diagnostics (Basel); 2023 Dec; 13(24):. PubMed ID: 38132219
[TBL] [Abstract][Full Text] [Related]
10. HDAC5-mediated PRAME regulates the proliferation, migration, invasion, and EMT of laryngeal squamous cell carcinoma via the PI3K/AKT/mTOR signaling pathway.
Yu L; Cao H; Yang JW; Meng WX; Yang C; Wang JT; Yu MM; Wang BS
Open Med (Wars); 2023; 18(1):20230665. PubMed ID: 36910848
[TBL] [Abstract][Full Text] [Related]
11. [Clinical features and prognosis of childhood B-lineage acute lymphoblastic leukemia expressing the
Zhang F; Lu AD; Zuo YX; Ding MM; Jia YP; Zhang LP
Zhongguo Dang Dai Er Ke Za Zhi; 2022 May; 24(5):543-549. PubMed ID: 35644195
[TBL] [Abstract][Full Text] [Related]
12. PRAME protein expression in DICER1-related tumours.
Thorner PS; Chong AS; Nadaf J; Benlimame N; Marrano P; Chami R; Fu L; Foulkes WD
J Pathol Clin Res; 2022 May; 8(3):294-304. PubMed ID: 35297207
[TBL] [Abstract][Full Text] [Related]
13. Lack of PRAME Expression in Cutaneous T-Cell Lymphomas.
Bui CM; Kitahara S; Shon W; Pukhalskaya T; Smoller BR
Dermatopathology (Basel); 2021 Dec; 9(1):11-16. PubMed ID: 35076507
[TBL] [Abstract][Full Text] [Related]
14. Cancer testis antigen PRAME: An anti-cancer target with immunomodulatory potential.
Naik A; Thomas R; Al-Khadairi G; Bacha R; Hendrickx W; Decock J
J Cell Mol Med; 2021 Nov; 25(22):10376-10388. PubMed ID: 34612587
[TBL] [Abstract][Full Text] [Related]
15. The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer.
Xu Y; Zou R; Wang J; Wang ZW; Zhu X
Cell Prolif; 2020 Mar; 53(3):e12770. PubMed ID: 32022332
[TBL] [Abstract][Full Text] [Related]
16. Growth inhibitor of human hepatic carcinoma HepG2 cells by evodiamine is associated with downregulation of PRAME.
Zhu H; Ge K; Lu J; Jia C
Naunyn Schmiedebergs Arch Pharmacol; 2019 Dec; 392(12):1551-1560. PubMed ID: 31359090
[TBL] [Abstract][Full Text] [Related]
17. PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer.
Al-Khadairi G; Naik A; Thomas R; Al-Sulaiti B; Rizly S; Decock J
J Transl Med; 2019 Jan; 17(1):9. PubMed ID: 30602372
[TBL] [Abstract][Full Text] [Related]
18. Methylation pattern of preferentially expressed antigen of melanoma in acute myeloid leukemia and myelodysplastic syndromes.
Qin YZ; Zhang YH; Qin XY; Zhu HH
Oncol Lett; 2017 Apr; 13(4):2823-2830. PubMed ID: 28454473
[TBL] [Abstract][Full Text] [Related]
19. Identification of Preferentially Expressed Antigen of Melanoma as a Potential Tumor Suppressor in Lung Adenocarcinoma.
Huang Q; Li L; Lin Z; Xu W; Han S; Zhao C; Li L; Cao W; Yang X; Wei H; Xiao J
Med Sci Monit; 2016 May; 22():1837-42. PubMed ID: 27241212
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
